The company has started to add bearish views on Wall Street as the healthcare giant's business practices draw public scrutiny, risking its prospects, worsened by its recent leadership change. Bank of ...

Under the new FDA guidelines, only people 65 and older and others with one or more health risk factors will be able to ...

Moderna, Inc. (NASDAQ:MRNA) today announced that it has submitted an application to the U.S. Food and Drug Administration (FDA) for review of its Spikevax 2025-2026 formula, targeting the SARS-CoV-2 ...

The FDA picked the LP.8.1 Covid strain for the fall vaccines, fueling concerns that the shots may be limited to only the most ...

I'm a clinical academic, which is quite a rare breed of doctor, because what I'm doing, along with other clinical academics, ...

In a major and controversial policy shift, the FDA announced in a New England Journal of Medicine article that updated ...

The notice came shortly after an advisory panel meeting at which members debated the pros and cons of asking manufacturers to ...

The FDA will encourage new clinical trials on the widely used vaccines before approving them for children and healthy adults.

Despite the fact that vaccines against COVID have already undergone strict safety reviews and that people continue to die ...

The covid booster clampdown is supported by many adherents of the “ Make America Healthy Again ” movement, which casts suspicion on traditional medicine. Some opponents of covid mRNA vaccines say ...

Elaine Chen covers biotech, co-writes The Readout newsletter, and co-hosts STAT’s weekly biotech podcast, The Readout Loud.

The FDA will limit the vaccine’s availability later this year to older adults and those who may be at risk of severe illness.